Ardelyx (ARDX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company vision and product overview

• Focus on first-in-class medicines addressing unmet medical needs, with two approved therapies: IBSRELA for IBS-C and XPHOZAH for phosphate lowering in end-stage renal disease patients on dialysis.

• IBSRELA launched in 2022, XPHOZAH approved in late 2022 and launched in 2023.

• Early-stage compounds in development, with updates expected early next year.

• Exploring partnerships and in-licensing to expand the pipeline.

Commercialization strategy and performance

• Both products use a targeted approach, focusing on high-prescribing physicians in established markets with high unmet need.

• IBSRELA generated $80M in 2023, with 2024 guidance of $140–$150M in net revenue.

• XPHOZAH achieved $37M+ in Q2 2024 revenue; guidance pending due to market uncertainty.

• Sales force expanded in 2024: 124 reps for IBSRELA, 60 area business directors for XPHOZAH.

Market dynamics and reimbursement

• IBSRELA targets adults as a second-line therapy, aiming for over $1B in peak sales before patent expiry by capturing 10%+ market share.

• Gross-to-net deductions for IBSRELA improve throughout the year, with Q1 typically highest due to insurance resets.

• XPHOZAH faces potential Medicare reimbursement changes in 2025, with 60% of patients on Medicare and 40% on other payers.

• Legislative (Kidney Patient Act) and litigation efforts underway to maintain Medicare access for XPHOZAH.